Patents Assigned to Atlantic Pharmaceuticals, Inc.
  • Patent number: 8647669
    Abstract: A dosage form from which a burst release of a drug contained within a tampered dosage form is reduced or retarded by the presence in or on the dosage form of a TPTA (Tamper Prone Therapeutic Agent) trap. If the dosage form has not been tampered with, the TPTA trap does not significantly interfere with the rate of release of the drug from the dosage form. However, if the dosage form has been physically tampered with, the TPTA trap reduces or retards burst release of the drug from the dosage form.
    Type: Grant
    Filed: April 11, 2013
    Date of Patent: February 11, 2014
    Assignee: Atlantic Pharmaceuticals, Inc.
    Inventor: Krishna Shukla
  • Publication number: 20130224265
    Abstract: A dosage form from which a burst release of a drug contained within a tampered dosage form is reduced or retarded by the presence in or on the dosage form of a TPTA (Tamper Prone Therapeutic Agent) trap. If the dosage form has not been tampered with, the TPTA trap does not significantly interfere with the rate of release of the drug from the dosage form. However, if the dosage form has been physically tampered with, the TPTA trap reduces or retards burst release of the drug from the dosage form.
    Type: Application
    Filed: April 11, 2013
    Publication date: August 29, 2013
    Applicant: Atlantic Pharmaceuticals, Inc.
    Inventors: Anthony Edward Soscia, Yingxu Peng, Yichun Sun, James R. Johnson
  • Patent number: 8507001
    Abstract: A dosage form from which a burst release of a drug contained within a tampered dosage form is reduced or retarded by the presence in or on the dosage form of a TPTA (Tamper Prone Therapeutic Agent) trap. If the dosage form has not been tampered with, the TPTA trap does not significantly interfere with the rate of release of the drug from the dosage form. However, if the dosage form has been physically tampered with, the TPTA trap reduces or retards burst release of the drug from the dosage form.
    Type: Grant
    Filed: December 3, 2012
    Date of Patent: August 13, 2013
    Assignee: Atlantic Pharmaceuticals, Inc.
    Inventor: Anthony Edward Soscia
  • Publication number: 20130095148
    Abstract: A dosage form from which a burst release of a drug contained within a tampered dosage form is reduced or retarded by the presence in or on the dosage form of a TPTA (Tamper Prone Therapeutic Agent) trap. If the dosage form has not been tampered with, the TPTA trap does not significantly interfere with the rate of release of the drug from the dosage form. However, if the dosage form has been physically tampered with, the TPTA trap reduces or retards burst release of the drug from the dosage form.
    Type: Application
    Filed: December 3, 2012
    Publication date: April 18, 2013
    Applicant: Atlantic Pharmaceuticals, Inc.
    Inventors: Anthony Edward Soscia, Yingxu Peng, Yichun Sun, James R. Johnson, Atul J. Shukla
  • Patent number: 8349362
    Abstract: A dosage form from which a burst release of a drug contained within a tampered dosage form is reduced or retarded by the presence in or on the dosage form of a TPTA (Tamper Prone Therapeutic Agent) trap. If the dosage form has not been tampered with, the TPTA trap does not significantly interfere with the rate of release of the drug from the dosage form. However, if the dosage form has been physically tampered with, the TPTA trap reduces or retards burst release of the drug from the dosage form.
    Type: Grant
    Filed: April 24, 2012
    Date of Patent: January 8, 2013
    Assignee: Atlantic Pharmaceuticals, Inc.
    Inventors: Anthony Edward Soscia, Yingxu Peng, Yichun Sun, James R. Johnson, Atul J. Shukla
  • Publication number: 20120207797
    Abstract: A dosage form from which a burst release of a drug contained within a tampered dosage form is reduced or retarded by the presence in or on the dosage form of a TPTA (Tamper Prone Therapeutic Agent) trap. If the dosage form has not been tampered with, the TPTA trap does not significantly interfere with the rate of release of the drug from the dosage form. However, if the dosage form has been physically tampered with, the TPTA trap reduces or retards burst release of the drug from the dosage form.
    Type: Application
    Filed: April 24, 2012
    Publication date: August 16, 2012
    Applicant: Atlantic Pharmaceuticals, Inc.
    Inventors: Anthony Edward Soscia, Yingxu Peng, Yichun Sun, James R. Johnson, Atul J. Shukla
  • Patent number: 8187636
    Abstract: A dosage form from which a burst release of a drug contained within a tampered dosage form is reduced or retarded by the presence in or on the dosage form of a TPTA (Tamper Prone Therapeutic Agent) trap. If the dosage form has not been tampered with, the TPTA trap does not significantly interfere with the rate of release of the drug from the dosage form. However, if the dosage form has been physically tampered with, the TPTA trap reduces or retards burst release of the drug from the dosage form.
    Type: Grant
    Filed: September 25, 2006
    Date of Patent: May 29, 2012
    Assignee: Atlantic Pharmaceuticals, Inc.
    Inventors: Anthony Edward Soscia, Yingxu Peng, Yichun Sun, James R. Johnson, Atul J. Shukla
  • Patent number: 6162829
    Abstract: The present invention relates to non-psychoactive derivatives of tetrahydro-cannabinol, which exhibit anti-inflammatory, analgesic and leukocyte antiadhesion activities. The invention includes novel derivatives of (3R,4R)-.DELTA..sup.8 -tetrahydrocannabinol-11-oic acids [hereinafter referred to as (3R,4R)-.DELTA..sup.8 -THC-11-oic acid], as well as pharmaceutical compositions containing the (3R,4R)-.DELTA..sup.8 -THC-11-oic acid derivatives. The invention further covers methods of administering the novel derivatives and pharmaceutical compositions as therapeutic agents in the treatment of pain and tissue inflammation. Non-psychoactive derivatives of .DELTA..sup.8 -THC-11-oic acid are described which have analgesic and anti-inflammatory properties.
    Type: Grant
    Filed: October 17, 1997
    Date of Patent: December 19, 2000
    Assignee: Atlantic Pharmaceuticals, Inc.
    Inventor: Sumner H. Burstein